Dr. Ahmed Salman, MD

Dr. Salman practices at MultiCare Tacoma General Hospital in Tacoma, Washington, part of MultiCare Health System.

Dr. Salman's NPI, 1528313152, was assigned on July 19, 2012. Dr. Salman holds New York license 311283.

Dr. Salman's primary practice is MultiCare Tacoma General Hospital, at 315 S Mlk Jr Way, Tacoma, WA 98405 in Pierce County. The practice phone is (253) 403-1000.

Dr. Salman's primary practice is MultiCare Tacoma General Hospital in Tacoma, Washington, part of MultiCare Health System. Dr. Salman is also affiliated with Rochester General Hospital. The medical group on file is MultiCare Indigo Urgent Care, Spokane, Newport Hwy. Dmand AI also links Dr. Salman to 3 more hospitals, 5 medical groups, 2 group practices and clinics, 1 behavioral health center and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Salman practices, 9 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Salman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Salman's licenses on file in 2 states: New York and Pennsylvania.

CMS data shows 11 Medicare services from Dr. Salman across 1 procedure code in 2024, all of them office visits, for 35 Medicare patients. Medicare paid $585 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Salman in 2024. The largest group is 75 to 84, with 15 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Salman's median patient age at 70, with 55% women.

In 2024, Dr. Salman wrote 107 Medicare Part D claims for 43 patients. 83% of them were for generic drugs. CMS names the drug for 20 of them, across 1 drug with 11 or more claims each, at $162 in total drug cost. In 2023, CMS named 25 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Salman for performance year 2024, reported through an alternative payment model (APM). Dr. Salman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Salman as offering telehealth.

Dmand AI links 54 papers to Dr. Salman, published from 2014 to 2025. 2018 was the busiest year, with 6. The most frequent topics are Malaria Vaccines, Protozoan Proteins and Plasmodium falciparum. Dr. Salman has published most often in Sci Rep. Dr. Salman's most frequent co-authors are Shahid Mushtaq Khan, MD, Shahid M. Khan, MD and Richard L. Alweis, MD.

CMS Open Payments shows 16 general payments to Dr. Salman from 9 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $60.